ruxolitinib
novartis,incyte
['ruxolitinib', 'rux,(-crux),(-trux),(-deruxtecan)']
congress #ash22 | discusses the results of phase ii trial of ruxolitinib for sr sclerotic cgvhd. n=47. overall cgvhd partial responses were seen in 47%; other responses included sd (13%), mixed responses/progression (27%) &amp; missing (13%). #gvhd #bmtsm 
A global online platform providing latest treatment options and medical information in graft-versus-host disease (GvHD). #gvhd